Meeting
2018 ASCO Annual Meeting
Comparative effectiveness of carboplatin-pemetrexed (Carbo-Pem) with vs. without bevacizumab (Bev) in patients with advanced non-squamous (Sq) non-small cell lung cancer (NSCLC).
Authors
Stephen Joseph Bagley
Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Stephen Joseph Bagley , Nandita Mitra , Neal J. Meropol , Benjamin Holzman , Roger B. Cohen , Corey J. Langer , Anil Vachani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9073)
DOI
10.1200/JCO.2018.36.15_suppl.9073
Abstract #
9073
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).
First Author: Caicun Zhou
Poster
2021 ASCO Annual Meeting
EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.
First Author: Christos Chouaid
Poster
2020 ASCO Virtual Scientific Program
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
First Author: Deborah Blythe Doroshow
Poster
2019 ASCO Annual Meeting
A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).
First Author: Yoshimasa Shiraishi